The aim of the current study was to investigate the prognostic value of SUV max in patients with completely resected early stage (stage I & II) NSCLC.
Lung cancer is leading cause of cancer-related death in the United States. In the United States, approximately 215,020 new cases of lung cancer are diagnosed each year; the estimated deaths were 161,840 in 2008 [1] .
Traditionally, early stage non-small cell lung cancer (NSCLC) is managed with surgical resection. In contrast to locally advanced and metastatic NSCLC, the prognosis following resection for early stage disease is favorable. In a number of reports, 5 year survival rates for patients with stage I disease range 60~75 %, while for stage II disease five-year survival rates vary from 36~60 % [2] [3] [4] [5] [6] . However, the recurrence rate after curative resection still remains high and approximately half of the patients may relapse and die within 5 years, and majority of these relapses are due to distant metastasis and occur within 2 years after complete resection [7, 8] .
Fluorine-18 fluorodeoxyglucose positron emission tomography (F-18 FDG PET) has been established as a standard imaging technique in staging, treatment monitoring, prediction of survival after treatment, and follow-up of NSCLC patients [9] [10] [11] [12] [13] [14] [15] . Maximal standardized uptake value (SUV max ) measured by F-18 FDG PET is a semiquantitative index reflecting tumor metabolism and activities.
Several previous studies suggested the prognostic role of F-18 FDG PET in patients with early stage NSCLC after complete resection [16] [17] [18] [19] [20] . Although different threshold SUV max values were proposed, high FDG uptake is associated with reduced overall survival and disease-free survival of patients with completely resected early stage NSCLC.
In the current study, we investigated the prognostic value of SUV max measured by preoperative F-18 FDG PET in patients with completely resected early stage (stage I & II) NSCLC.
Materials and methods
Patient eligibility. Retrospectively, we reviewed lung cancer registry at our institution and identified early stage NSCLC (stage I and II) based on histologic examinations of resected specimens between 2005 and 2009. Patients were excluded from the current study if they had received neoadjuvant or adjuvant chemotherapy or radiation treatment, had any previous lung cancer, multiple primary cancer. Seventy six patients met these inclusion and exclusion criteria. All 76 patients underwent preoperative F-18 FDG PET/CT, computed tomography (CT), brain magnetic resonance imaging (MRI), and bone scan. This study was approved by our institutional review board and written informed consent was obtained from each patient.
Clinical follow-up and End point assessment. During the follow-up, complete physical examination, chest CT, routine laboratory test were performed every 6 months. Recurrence was defined as any appearing of new cancer focus in a diseasefree patient. The time interval between the surgery and cancer recurrence were determined. The duration of disease-free survival (DFS) was calculated as the time interval between the surgery date and date of the cancer recurrence, death without evidence of recurrence, or the last clinical contact. The followup was completed by 30 th , April 2010. F-18 FDG PET/CT. F-18 FDG PET/CT image was done with a dedicated PET/CT scanner (Gemini, Philips, Milpitas, CA, USA), consisting of a dedicated germanium oxyorthosilicate full-ring PET scanner and a dual slice helical CT scanner. Standard patient preparation included at least 8 hours fasting and a serum glucose level of less than 120 mg/dL before F-18 FDG administration (mean dose, 383.7±47.4 MBq; range, 314.5~488.4 MBq). PET/CT imaging was performed 60 minutes after injection of F-18 FDG. At 60 minutes after administration of F-18 FDG, low-dose CT (30 mAs, 120kV) covering area from the base of the skull to the proximal thighs was performed for the purpose of attenuation correction and precise anatomical localization. Thereafter, emission scan was conducted in the 3-dimensional mode. Emission scan time per bed position was 3 minutes; 9 bed positions were acquired. To calculate maximal standardized uptake values (SUV max ), manually defined circular regions of interest (ROI) were drawn on the attenuation corrected emission images throughout axial planes in which a suspicious lesion could be delineated.
Statistical analysis. All numerical data was expressed as mean±SD. Survival analysis was conducted using KaplanMeier analysis, and survival curves stratified by age, sex, mediastinal lymph node involvement, SUV max , and TNM staging were generated. Log rank test was used to compare the survival between each group. Overall survival was measured from the date of surgery to the date of death or most recent follow-up. Also, disease free survival (DFS) was measured from the time of surgery to the date of first recurrence of NSCLC. Independent predictive factors for survival were determined using Cox proportional hazard model. Receiver operating characteristic curve (ROC) analysis was performed for the prediction of survival after treatment using quantitative indices of F-18 FDG PET/CT. Data analyses were conducted with MedCalc. Statistical significance was defined as P<0.05.
Results
Patient characteristics and follow-up. The characteristics of the patients are given in Table 1 . Forty-eight patients were male (63.2%) The mean age at the time of diagnosis was 64.2 years (range, 26~81 years). Thirty-six patients had adenocarcinoma and 24 patients had squamous cell carcinoma. The median follow-up time was overall 30.8 month (range, 0.9~59.1 month), for surviving patients 31.3 month (range, 3.2~59.1 month), and for deceased patients 15.3 month (range, 0.9~48.9 month).
Exploring a cutoff point of the SUV max . The optimal cutoff values of SUV max for estimation of death and cancer recurrence was calculated. For overall survival, SUV max >6.7 was chosen (area under curve (AUC), 0.890; standard error, 0.0489; 95% confidence interval (CI), 0.798~0.951; p=0.0001). For disease free survival, SUV max >5.9 was chosen (AUC, 0.775, standard error, 0.0592; 95% CI, 0.665~0.863, p=0.0001).
Overall survival. Figure 1 demonstrates the Kaplan-Meier survival curves of the two groups of patients with SUV max >6.7 or SUV max ≤6.7. Six patients (27.3%) with a tumor SUV max >6.7 and none of patients with tumor SUV max ≤6.7 died during follow-up period. The median survival of the patients with tumor SUV max ≤6.7 was 48.9 months and was significantly Figure 2A (Log rank test, Χ 2 =10.6, p=0.0011). For stage II patients (n=26), the survival was also significantly better in patients with tumor SUV max ≤6.7 than the patients with tumor SUV max >6.7 (median survival, 48.9 month) as shown in Figure  2B (Log rank test, Χ 2 =5.13, p=0.0234). Disease free survival. During the follow up, the recurrence was found in 5 patients (6.6%) in group with tumor SUV max ≤5.9 and in 17 patients (22.4%) in group with tumor SUV max >5.9. As shown in figure 3 , the overall DFS was better in patients with tumor SUV max ≤5.9 than the patients with tumor SUV max >5.9. The median survival of the patients with tumor SUV max ≤5.9 was 31.7 months (Log rank test, Χ 2 =16, p=0.0001).
For stage I patients (n=50), the survival was significantly better in patients with tumor SUV max ≤5.9 than the patients with tumor SUV max >5.9 (median survival, 34 month) as shown in Figure 4A (Log rank test, Χ 2 =6.99, p=0.0082). For stage II patients (n=26), the survival was also significantly better in patients with tumor SUV max ≤6.7 than the patients with tumor SUV max >6.7 (median survival, 16.5 month) as shown in Figure  4B (Log rank test, Χ 2 =4.09, p=0.0431). Prediction of overall survival and DFS. Table 2 shows the univariate and multivariate analyses for the prediction of overall survival and DFS of the entire cohort. Cox proportional hazard regression analysis reveals that the SUV max was the potent predictor of overall survival. In order to define the prognostic factors for DFS, multivariate survival analysis was performed using Cox proportional hazard model. As shown in Table 2 , the potent predictor of DFS was also SUV max .
Discussion
The current study revealed that F-18 FDG PET/CT could predict tumor recurrence and survival in surgically resected early stage (stage I & II) NSCLC. Also, F-18 FDG PET/CT could predict prognosis of early stage NSCLC even stratified by pathologic stages. Among various variables, the SUV max of primary tumor was the most potent predictor of overall survival and DFS in the early stage NSCLC patients.
A recent systematic review identified 9 studies that examined FDG uptake and prognosis in patients with surgically treated stage I NSCLC [21] . Although significant heterogeneity existed across 9 studies included in their review, they found substantial evidence that the degree of FDG uptake in the primary tumor is associated with prognosis in surgically resected stage I NSCLC [21] . On the contrary to the current study, the majority of previous studies regarding the prognostic role of F-18 FDG PET in early stage NSCLC recruited stage I patients for reasons of study homogeneity [17-19, 21, 22] . Most of these studies evaluated SUV max in primary tumor before treatment and they founded that FDG uptake in primary tumor could predict overall survival and tumor recurrence with different thresholds of SUV max .
Interestingly, a recent study conducted the prognostic role of F-18 FDG PET in homogenous stage I adenocarcinoma patients concluded that patients with higher preoperative SUV max values have significantly higher recurrence rates [19] . They insisted that even in stage I adenocarcinoma patients, mass size and SUV max are related to higher rates of recurrence, and thus, these patients require more attentive observation after curative resection [19] . The great strength of their study is that, to control for potential bias due to stage and histology, the subjects were confined the pathologically proven stage I adenocarcinoma. Similar to the current study, Hanin et al [16] studied the prognostic value of PET FDG in patients with completely resected 96 NSCLC patients with stage I & II. They found that high FDG uptake (SUV max >7.8) is associated with reduced overall survival and DFS of patients with completely resected stage I-II NSCLC. Subgroup analyses according to the pathologic stages of their study cohort found that F-18 FDG PET could predict overall survival and DFS in patients with stage I but not in stage II NSCLC, which is different finding compared to the current study.
According to another interesting study by Dooms et al [20] , SUV max and partial volume corrected SUV max (PVC SUV max ) were associated with an increased risk of death in univariate analysis. However, after correcting for stage, tumor size, and age in multivariate analysis, only PVC SUV max was the potent predictor of the survival in their study. In their study, why the PVC SUV max was potent predictor of prognosis could be explained by high Ki-67 and high CAIX length density by multivariate logistic regression analysis.
However, a recent study reported limited prognostic value of SUV max in early stage (stage I & II) NSCLC [23] . They found that each doubling of SUV max as determined by preoperative PET is associated with a 1.28-fold increase in hazard of death in early-stage (I & II) NSCLC. However, they noted that preoperative SUV max is not an independent predictor of overall survival. Similar disappointing result was also noted in advanced NSCLC. Why the SUVmax of the primary tumor could not be prognostic factor may be explained by various factors such as dichotomized age, absence of multivariate analysis, excluding age factor and tumor size in multivariate analysis, and small size of the primary tumor [23] . However, in the current, after considering of all these confounding factors, the SUV max was the most potent predictor of overall survival and DFS in surgically resected early stage NSCLC even after stratified by pathologic stages.
A number of previous studies have tried to set optimal SU-V max cut-off values to predict patient`s prognosis in early stage NSCLC with different values of SUV max [16~22] . In the current study, the optimal cut-off values of SUV max for prediction of overall were 6.7 and 5.9 for DFS. Previous several studies set the same SUVmax for estimation of overall survival and DFS [16~22] . The only one value of SUV max might not suitable for prediction of different nature of overall survival and DSF done in previous studies. In the current study, we used different values of SUV max for prediction of overall survival and DFS in entire study cohort and subgroups stratified by pathologic stages. This kind of analysis could strengthen the prognostic value of SUV max in early stage NSCLC for estimation prognosis.
Some limitations of current study should be considered. First, the current study was the retrospective analysis of early stage NSCLC. Second, as previously reported [23] , we could not set the tumor stage specific optimal cut-off values of SUV max because of relatively small population of pathologic stage II patients.
In conclusion, high FDG uptake measured by F-18 FDG PET/CT might have a prognostic value for overall survival and DFS in surgically resected early stage (stage I & II) NSCLC even after stratified by pathologic stages.
